menu
    • menu

    Company profile for CEL-SCI

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CEL-SCIUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    8229 Boone Boulevard, Suite 802 Vienna, VA 22182 USA
    Telephone
    Telephone
    703-506-9460
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://cel-sci.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CEL-SCI Announces Closing of $10 Million Public Offering
    CEL-SCI Announces Closing of $10 Million Public Offering

    29 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250829759392/en/CEL-SCI-Announces-Closing-of-%2410-Million-Public-Offering

    BUSINESSWIRE
    29 Aug 2025
    Share Share
    CEL-SCI Announces Pricing of $10 Million Public Offering
    CEL-SCI Announces Pricing of $10 Million Public Offering

    28 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250827425347/en/CEL-SCI-Announces-Pricing-of-%2410-Million-Public-Offering

    BUSINESSWIRE
    28 Aug 2025
    Share Share
    CEL-SCI Announces Proposed Public Offering
    CEL-SCI Announces Proposed Public Offering

    27 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250827778416/en/CEL-SCI-Announces-Proposed-Public-Offering

    BUSINESSWIRE
    27 Aug 2025
    Share Share
    CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
    CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

    14 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250814408987/en/CEL-SCI-Reports-Fiscal-Third-Quarter-2025-Financial-Results

    BUSINESSWIRE
    14 Aug 2025
    Share Share
    CEL-SCI Files Multikine Immunotherapy in Saudi Arabia
    CEL-SCI Files Multikine Immunotherapy in Saudi Arabia

    13 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250813431066/en/CEL-SCIs-Multikine-Head-and-Neck-Cancer-Immunotherapy-Breakthrough-Medicine-Designation-Filed-in-Saudi-Arabia-Allows-for-Patient-Access-and-ReimbursementSale-Upon-Granting-of-the-Designation-Which-Takes-Approximately-60-Days-Based-on-SFDA-Timeline

    BUSINESSWIRE
    13 Aug 2025
    Share Share
    CEL-SCI Closes $5.7M Offering Under NYSE American Rules
    CEL-SCI Closes $5.7M Offering Under NYSE American Rules

    14 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250714581614/en/CEL-SCI-Announces-Closing-of-%245.7-Million-Offering-Priced-At-The-Market-Under-NYSE-American-Rules

    BUSINESSWIRE
    14 Jul 2025
    Share Share

    ABOUT THIS PAGE

    Contact CEL-SCI and get a quotation

    CEL-SCI is a supplier offers 1 products (APIs, Excipients or Intermediates).

    Find a price of LEUKOCYTE INTERLEUKIN, INJECTION bulk offered by CEL-SCI

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search